Do analysts prefer SPRO or ACB?

Spero Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 380.00%. Given Spero Therapeutics' higher possible upside, research analysts clearly believe Spero Therapeutics is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts prefer SIGA or SPRO?

Spero Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 380.00%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spero Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25

Spero Therapeutics (SPRO) Competitors

$1.25 -0.01 (-0.79%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$1.25 0.00 (0.00%)

As of 09/24/2026 07:30 PM Eastern

Compare

SPRO vs. ACB, ZNTL, CRDL, SIGA, and DERM

Should you buy Spero Therapeutics stock or one of its competitors? Spero Therapeutics's main competitors and comparable companies include Aurora Cannabis (ACB), Zentalis Pharmaceuticals (ZNTL), Cardiol Therapeutics (CRDL), Siga Technologies (SIGA), and Journey Medical (DERM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Spero Therapeutics compare to Aurora Cannabis?

Spero Therapeutics (NASDAQ:SPRO) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Spero Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.11	11.36
Aurora Cannabis	$247.82M	1.09	-$88.13M	-$1.41	N/A

In the previous week, Aurora Cannabis had 3 more articles in the media than Spero Therapeutics. MarketBeat recorded 4 mentions for Aurora Cannabis and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.82 beat Aurora Cannabis' score of 0.60 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Spero Therapeutics	Very Positive
Aurora Cannabis	Positive

Spero Therapeutics has a net margin of 24.90% compared to Aurora Cannabis' net margin of -32.26%. Spero Therapeutics' return on equity of 16.17% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	16.17%	12.57%
Aurora Cannabis	-32.26%	4.37%	3.45%

Spero Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 380.00%. Given Spero Therapeutics' higher possible upside, research analysts clearly believe Spero Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Spero Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

Summary

Spero Therapeutics beats Aurora Cannabis on 11 of the 16 factors compared between the two stocks.

How does Spero Therapeutics compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Zentalis Pharmaceuticals presently has a consensus target price of $6.75, suggesting a potential upside of 145.45%. Spero Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 380.00%. Given Spero Therapeutics' higher probable upside, analysts clearly believe Spero Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Spero Therapeutics has a net margin of 24.90% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Spero Therapeutics' return on equity of 16.17% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Spero Therapeutics	24.90%	16.17%	12.57%

Spero Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	2.92	-$137.06M	-$1.95	N/A
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.11	11.36

25.6% of Spero Therapeutics shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zentalis Pharmaceuticals has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market.

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Zentalis Pharmaceuticals and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.82 beat Zentalis Pharmaceuticals' score of 0.90 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Positive
Spero Therapeutics	Very Positive

Summary

Spero Therapeutics beats Zentalis Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Spero Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Spero Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.11	11.36

Spero Therapeutics has a net margin of 24.90% compared to Cardiol Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 16.17% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Spero Therapeutics	24.90%	16.17%	12.57%

Cardiol Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 478.03%. Spero Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 380.00%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Cardiol Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

In the previous week, Cardiol Therapeutics had 6 more articles in the media than Spero Therapeutics. MarketBeat recorded 7 mentions for Cardiol Therapeutics and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.82 beat Cardiol Therapeutics' score of 0.54 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Positive
Spero Therapeutics	Very Positive

Summary

Spero Therapeutics beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Spero Therapeutics compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, Siga Technologies and Siga Technologies both had 1 articles in the media. Spero Therapeutics' average media sentiment score of 1.82 beat Siga Technologies' score of 1.13 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Siga Technologies	Positive
Spero Therapeutics	Very Positive

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spero Therapeutics has a net margin of 24.90% compared to Siga Technologies' net margin of -5.19%. Spero Therapeutics' return on equity of 16.17% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Spero Therapeutics	24.90%	16.17%	12.57%

Spero Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 380.00%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Siga Technologies has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Siga Technologies has higher revenue and earnings than Spero Therapeutics. Siga Technologies is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.47	$23.28M	-$0.05	N/A
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.11	11.36

Summary

Spero Therapeutics beats Siga Technologies on 11 of the 15 factors compared between the two stocks.

How does Spero Therapeutics compare to Journey Medical?

Spero Therapeutics (NASDAQ:SPRO) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Spero Therapeutics has a net margin of 24.90% compared to Journey Medical's net margin of -8.95%. Spero Therapeutics' return on equity of 16.17% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	16.17%	12.57%
Journey Medical	-8.95%	-20.23%	-6.60%

Spero Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.09	$8.57M	$0.11	11.36
Journey Medical	$61.86M	2.88	-$11.43M	-$0.22	N/A

Spero Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 380.00%. Journey Medical has a consensus price target of $14.00, suggesting a potential upside of 121.52%. Given Spero Therapeutics' higher probable upside, equities research analysts clearly believe Spero Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Journey Medical had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 3 mentions for Journey Medical and 1 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 1.82 beat Journey Medical's score of 0.70 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Spero Therapeutics	Very Positive
Journey Medical	Positive

Summary

Spero Therapeutics beats Journey Medical on 11 of the 15 factors compared between the two stocks.

Get Spero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRO vs. The Competition

Export

Metric	Spero Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$79.20M	$12.63B	$7.32B	$13.29B
Dividend Yield	N/A	2.62%	2.52%	12.57%
P/E Ratio	11.36	789.89	274.41	25.76
Price / Sales	1.09	1,003.44	688.46	106.29
Price / Cash	8.94	88.64	77.80	52.76
Price / Book	1.19	10.69	10.52	6.34
Net Income	$8.57M	$2.83B	$3.49B	$360.00M
7 Day Performance	10.62%	-0.52%	-0.94%	-0.16%
1 Month Performance	1.63%	-2.34%	-4.24%	-4.08%
1 Year Performance	-35.57%	3.11%	16.38%	5.97%

Spero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRO Spero Therapeutics	3.96 of 5 stars	$1.25 -0.8%	$6.00 +380.0%	-36.5%	$79.20M	$66.80M	11.36	150	Positive News
ACB Aurora Cannabis	1.129 of 5 stars	$3.82 +0.1%	N/A	-19.7%	$247.37M	$247.82M	N/A	1,028	Gap Down
ZNTL Zentalis Pharmaceuticals	3.7711 of 5 stars	$3.17 -9.3%	$6.75 +112.7%	+80.9%	$227.56M	N/A	N/A	106
CRDL Cardiol Therapeutics	2.7656 of 5 stars	$1.85 -7.3%	$10.00 +442.0%	+58.7%	$214.35M	N/A	N/A	18	News Coverage Analyst Forecast
SIGA Siga Technologies	0.4247 of 5 stars	$2.96 -6.2%	N/A	-63.5%	$212.32M	$53.66M	N/A	49

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRO) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spero Therapeutics (SPRO) Competitors

SPRO vs. ACB, ZNTL, CRDL, SIGA, and DERM

How does Spero Therapeutics compare to Aurora Cannabis?

Summary

How does Spero Therapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Spero Therapeutics compare to Cardiol Therapeutics?

Summary

How does Spero Therapeutics compare to Siga Technologies?

Summary

How does Spero Therapeutics compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO vs. The Competition

Spero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spero Therapeutics (SPRO) Competitors

SPRO vs. ACB, ZNTL, CRDL, SIGA, and DERM

How does Spero Therapeutics compare to Aurora Cannabis?

Do institutionals & insiders have more ownership in SPRO or ACB?

Which has higher earnings and valuation, SPRO or ACB?

Does the media favor SPRO or ACB?

Is SPRO or ACB more profitable?

Do analysts prefer SPRO or ACB?

Which has more volatility and risk, SPRO or ACB?

Summary

How does Spero Therapeutics compare to Zentalis Pharmaceuticals?

Do analysts recommend ZNTL or SPRO?

Is ZNTL or SPRO more profitable?

Which has higher valuation and earnings, ZNTL or SPRO?

Do institutionals and insiders hold more shares of ZNTL or SPRO?

Which has more risk & volatility, ZNTL or SPRO?

Does the media favor ZNTL or SPRO?

Summary

How does Spero Therapeutics compare to Cardiol Therapeutics?

Which has preferable earnings and valuation, CRDL or SPRO?

Is CRDL or SPRO more profitable?

Do analysts prefer CRDL or SPRO?

Do institutionals & insiders hold more shares of CRDL or SPRO?

Which has more volatility and risk, CRDL or SPRO?

Does the media favor CRDL or SPRO?

Summary

How does Spero Therapeutics compare to Siga Technologies?

Does the media favor SIGA or SPRO?

Do insiders & institutionals hold more shares of SIGA or SPRO?

Is SIGA or SPRO more profitable?

Do analysts prefer SIGA or SPRO?

Which has more risk & volatility, SIGA or SPRO?

Which has stronger valuation and earnings, SIGA or SPRO?

Summary

How does Spero Therapeutics compare to Journey Medical?

Is SPRO or DERM more profitable?

Which has more risk & volatility, SPRO or DERM?

Which has higher earnings and valuation, SPRO or DERM?

Do analysts recommend SPRO or DERM?

Do insiders and institutionals hold more shares of SPRO or DERM?

Does the media refer more to SPRO or DERM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO vs. The Competition

Spero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools